FDA Not Following Up On Follow-On, Sandoz Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has not yet communicated to Sandoz any timeline for completing market authorization for the follow-on biologic Omnitrope (recombinant human growth hormone), in spite of a federal judge's ruling stipulating the agency make a decision
You may also be interested in...
Omnitrope Gains Final EU Approval
Sandoz will launch the Genotropin follow-on in Germany and Austria in the coming days.
Omnitrope Gains Final EU Approval
Sandoz will launch the Genotropin follow-on in Germany and Austria in the coming days.
FDA Must Take Action On Sandoz' Omnitrope Application, U.S. District Court says
The agency sees three options – appeal, approve or put to a hearing – following the decision which found that FDA had failed to meet its statutory timetable.